Psoriasis is a chronic, recurrent, and incurable autoimmune disease in which the body mistakenly attacks its own tissue, ...

Psoriasis is a chronic, immune-mediated skin condition. It causes red, scaly, itchy, often inflamed patches. Because the underlying issue involves immune response and skin-cell overproduction, there’s ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. We conducted a phase 3, double-blind, randomized, ...

Home remedies can sometimes soothe scalp psoriasis, an autoimmune, inflammatory condition marked by itching, irritation, and flaky, scaly skin. Still, research on the safety and effectiveness of home ...

When psoriasis develops on the scalp, hair loss sometimes follows. While hair tends to regrow once the scalp psoriasis clears, there are things you can do right now to prevent further hair loss. 1.

If you have psoriasis on your scalp, it can cause redness, thick scales or patches, itching, and even pain. It can also cause temporary hair loss. It’s similar to psoriasis on other parts of the body, ...

Guselkumab demonstrated strong efficacy in treating moderate to severe scalp psoriasis, especially in individuals with skin of color, achieving nearly 70% complete scalp clearance by week 48. The ...

KUTV — Plaque psoriasis is a chronic, inflammatory skin disease that affects many people. Symptoms, which include itch, scaling, redness, and flaking, can have a significant negative impact on ...

In the VISIBLE trial, guselkumab led to significant and sustained improvements in scalp psoriasis severity and quality of life in patients with skin of color through 48 weeks. Researchers evaluated ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients randomized ...

(RTTNews) - Johnson & Johnson (JNJ) Friday reported positive Phase 3 ICONIC-TOTAL data for Icotrokinra, a once-daily oral peptide that selectively inhibits the IL-23 receptor. The company noted that ...